The Gly82Ser polymorphism in the receptor for advanced glycation endproducts increases the risk for coronary events in the general population
(2024) In Scientific Reports 14(1).- Abstract
The receptor for advanced glycation endproducts (RAGE) has pro-inflammatory and pro-atherogenic effects. Low plasma levels of soluble RAGE (sRAGE), a decoy receptor for RAGE ligands, have been associated with increased risk for major adverse coronary events (MACE) in the general population. We performed a genome-wide association study to identify genetic determinants of plasma sRAGE in 4338 individuals from the cardiovascular arm of the Malmö Diet and Cancer study (MDC-CV). Further, we explored the associations between these genetic variants, incident first-time MACE and mortality in 24,640 unrelated individuals of European ancestry from the MDC cohort. The minor alleles of four single nucleotide polymorphisms (SNPs): rs2070600,... (More)
The receptor for advanced glycation endproducts (RAGE) has pro-inflammatory and pro-atherogenic effects. Low plasma levels of soluble RAGE (sRAGE), a decoy receptor for RAGE ligands, have been associated with increased risk for major adverse coronary events (MACE) in the general population. We performed a genome-wide association study to identify genetic determinants of plasma sRAGE in 4338 individuals from the cardiovascular arm of the Malmö Diet and Cancer study (MDC-CV). Further, we explored the associations between these genetic variants, incident first-time MACE and mortality in 24,640 unrelated individuals of European ancestry from the MDC cohort. The minor alleles of four single nucleotide polymorphisms (SNPs): rs2070600, rs204993, rs116653040, and rs7306778 were independently associated with lower plasma sRAGE. The minor T (vs. C) allele of rs2070600 was associated with increased risk for MACE [HR 1.13 95% CI (1.02–1.25), P = 0.016]. Neither SNP was associated with mortality. This is the largest study to demonstrate a link between a genetic sRAGE determinant and CV risk. Only rs2070600, which enhances RAGE function by inducing a Gly82Ser polymorphism in the ligand-binding domain, was associated with MACE. The lack of associations with incident MACE for the other sRAGE-lowering SNPs suggests that this functional RAGE modification is central for the observed relationship.
(Less)
- author
- organization
-
- Cardiac Inflammation Research Group (research group)
- Cardiovascular Research - Translational Studies (research group)
- EXODIAB: Excellence of Diabetes Research in Sweden
- MAX IV, User office
- Genetic and Molecular Epidemiology (research group)
- Cardiovascular Research - Hypertension (research group)
- Nutrition Epidemiology (research group)
- EpiHealth: Epidemiology for Health
- Cardiovascular Research - Epidemiology (research group)
- Internal Medicine - Epidemiology (research group)
- Diabetes - Cardiovascular Disease (research group)
- Cardiovascular Research - Immunity and Atherosclerosis (research group)
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- publishing date
- 2024-12
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scientific Reports
- volume
- 14
- issue
- 1
- article number
- 11567
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85194020956
- pmid:38773223
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-024-62385-5
- language
- English
- LU publication?
- yes
- id
- 34a34779-360f-4604-b50c-38413ef436f8
- date added to LUP
- 2024-06-13 14:42:28
- date last changed
- 2024-11-15 07:48:59
@article{34a34779-360f-4604-b50c-38413ef436f8, abstract = {{<p>The receptor for advanced glycation endproducts (RAGE) has pro-inflammatory and pro-atherogenic effects. Low plasma levels of soluble RAGE (sRAGE), a decoy receptor for RAGE ligands, have been associated with increased risk for major adverse coronary events (MACE) in the general population. We performed a genome-wide association study to identify genetic determinants of plasma sRAGE in 4338 individuals from the cardiovascular arm of the Malmö Diet and Cancer study (MDC-CV). Further, we explored the associations between these genetic variants, incident first-time MACE and mortality in 24,640 unrelated individuals of European ancestry from the MDC cohort. The minor alleles of four single nucleotide polymorphisms (SNPs): rs2070600, rs204993, rs116653040, and rs7306778 were independently associated with lower plasma sRAGE. The minor T (vs. C) allele of rs2070600 was associated with increased risk for MACE [HR 1.13 95% CI (1.02–1.25), P = 0.016]. Neither SNP was associated with mortality. This is the largest study to demonstrate a link between a genetic sRAGE determinant and CV risk. Only rs2070600, which enhances RAGE function by inducing a Gly82Ser polymorphism in the ligand-binding domain, was associated with MACE. The lack of associations with incident MACE for the other sRAGE-lowering SNPs suggests that this functional RAGE modification is central for the observed relationship.</p>}}, author = {{Grauen Larsen, Helena and Sun, Jiangming and Sjögren, Marketa and Borné, Yan and Engström, Gunnar and Nilsson, Peter and Orho-Melander, Marju and Goncalves, Isabel and Nilsson, Jan and Melander, Olle and Schiopu, Alexandru}}, issn = {{2045-2322}}, language = {{eng}}, number = {{1}}, publisher = {{Nature Publishing Group}}, series = {{Scientific Reports}}, title = {{The Gly82Ser polymorphism in the receptor for advanced glycation endproducts increases the risk for coronary events in the general population}}, url = {{http://dx.doi.org/10.1038/s41598-024-62385-5}}, doi = {{10.1038/s41598-024-62385-5}}, volume = {{14}}, year = {{2024}}, }